Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2722 in Moderate to Severe Atopic Dermatitis
NCT06552520Phase 3Active, not recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing TQH2722 injection with Placebo of TQH2722 injection (2 arms). Primary endpoints: Eczema Area and Severity Index 75% improvement at 16 weeks and Investigator's Global Assessment score of 0 or 1 at 16 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
TQH2722
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06552520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552520.